...
Items | Hierarchy/Topic | EARLY VISIBILITY OF PROPOSED CONTENT CHANGES | Planned Release timing (*this is provisional only and is subject to change) |
---|---|---|---|
1. | Clinical Finding | Update for Concepts Using 'Caused by' Clinical finding concepts containing "Caused by" in their FSN will be reviewed and will be updated (if applicable) according to the editorial guidelines related to causation here. There is one area where work is still in progress:
| 2024 International Release |
2. | Procedure | Update Hierarchy 363680008|Radiographic imaging Procedure (procedure)|and Descendants A Briefing Note documenting the proposed changes for the hierarchy 363680008|Radiographic imaging procedure (procedure)| and descendants was shared with the Editorial Advisory Group, Clinical Leads Group, Member Forum, Content Managers Advisory Group, and other key stakeholders in July 2023. Feedback was received from a wide range of stakeholders. In response to this feedback, the proposed changes to the hierarchy have been modified. These modifications will address issues raised in the feedback. This Informational Briefing Note summarizes the changes that will be implemented. Implementation of the content changes will commence in Q4 2023. The updates will be implemented in sub-hierarchies and promoted over a number of international monthly releases until complete. | Ongoing in phases across 2024 International Releases Please see item below - 42687005|Lymphangiogram (procedure)| and subtypes - July 2024 release |
3. | Content Improvement | Updates to the Inactivation Reason and Historical Association for 'On Examination' and 'Complaining of' Inactive Content Many of the 'on examination' and 'complaining of' concepts were previously inactivated with the inactivation reason of |Moved elsewhere| with a historical association value |Extension Namespace 1000000|. This content will be updated with an inactivation reason of |Non-conformance to editorial policy| and a historical association of |Alternative| to a suitable international concept. | Q3 2024 International Release |
4. | Social Context | Inactivation of Race and Ethnicity Concepts Based on discussions with the Member Forum, all subtypes of 372148003 |Ethnic group (ethnic group)| and most subtypes of 415229000 |Racial group (racial group)| will be inactivated as out of scope for the International release. While all subtypes of 372148003 |Ethnic group (ethnic group)| will be inactivated, the top level concept will be retained for extensions to add their local concepts. All subtypes of 415229000 |Racial group (racial group)| will be inactivated except for the following:
A briefing note is available here. | July 2024 International Release |
5. | Clinical Finding/Procedure | Patient/Subject concepts in the Clinical finding and Procedure Hierarchies Concepts in the Clinical finding and Procedure hierarchies that contain the explicit context of patient or subject will be inactivated and replaced with concepts without this explicit context. For further information please see briefing note. | On hold - to be determined |
6. | Clinical Finding | Inactivation of Mechanical Complication of <x> Device In October 2023 the Editorial Advisory Group made a decision that the concepts that represent a mechanical complication of <x> device are ambiguous. Following this a briefing note was shared with the community of practice to both inform and collect feedback. This feedback has been reviewed and the work will be proceeding. The concepts will be inactivated as ambiguous with a historical association to 473023007 |Complication associated with device (disorder)| or a suitable subtype. | Q3 2024 International Release |
7. | Dose Forms | Pharmaceutical Dose Forms with Two or More Intended Sites Pharmaceutical Dose Forms with more than one intended site will use “and” in their descriptions and include all intended sites in the model. By representing combinations of intended sites as a conjunction ('and' in the description) this will facilitate searching by end users. The concepts are logically modeled as conjunction. Existing dose forms with "or" will be updated to "and" in their descriptions, this will be included in the Editorial Guide. 9 clinical drugs using these dose forms will correspondingly have their descriptions updated to 'and'. Note - pharmaceutical dose forms with two or more administration methods: | Q3 2024 International Release |
8. | Clinical Finding | Substance Abuse/Use There has been a shift from the term "substance abuse" to a more nuanced understanding of substance use disorders in this domain which is reflected in both ICD-11 and DSM-5 indicating a greater emphasis on the spectrum of substance-related problems. Several members have expressed the need for content updates to incorporate this change and to simplify the translation process. Consequently, efforts to revise the content associated with 66214007 |Substance abuse (disorder)| will begin and is expected to be completed by the end of Q2. An example of the content structure and terming using opioid use is shown. Specifically, descriptions will be added with “harmful pattern of X substance use” replacing the term “abuse” in the FSN and PT however the “abuse” descriptions are persisted as synonyms to facilitate searching. In most cases there is no change in meaning, therefore the concepts will not be inactivated. Approximately 100 existing concepts relating to “abuse” will be affected together with the addition of new concepts to represent “harmful episode” and the higher level “X substance use disorder | Q3 2024 International Release |
9. | Clinical Finding | Inactivation of Complication Disorder Concepts (371 concepts) The inactivation of concepts that reference “complication” without specifying the nature of the complication is planned. The primitive “Complication (disorder)” grouper was inactivated in 2022 due to a lack of consistency or definition of what would properly be assigned as a subtype. The concepts will be inactivated with inactivation reason “Classification derived concept” and replacement by the parent concept. For further information please see this briefing note. | Beginning June 2024 International Release and then subsequent releases until complete |
10. | Observable Entity/Procedure | Update Role Grouping for Observable Entity and Evaluation Procedure Concepts Currently, Observable Entity concepts’ attributes are self-grouped in the international edition. Based on recommendation by the Modeling Advisory Group (MAG), the policy has changed to group these attributes together in order to support modeling concepts with multiple observations and address inconsistent modeling between evaluation procedures and observable entities. The same changes will be applied to the concepts in the evaluation procedure hierarchy that are modeled with applicable self-grouped attributes. Please see this briefing note for details. Please note that the scope of this change is limited to implementation of the updated role grouping MRCM rules for the observable entity and evaluation procedure hierarchies. There are areas in these subhierarchies that require content improvements , including but not limited to the following areas: complement assays, autoantibody measurements, concepts that refer to more than one Component (examples: ratios and concepts with “And”), Components including “Free” and “Total," concepts with fully defined parents, and procedure concepts modeled with a combination of evaluation procedure attributes and general procedure attributes. Some of the issues were already known and some were identified during this work. These improvements are not in the scope of this work and will be undertaken in future work including the QI project and improvements in other hierarchies including substance and specimen. Some of the issues require feedback from SMEs and/or communication with the Members. If required, editorial guidelines will be updated accordingly. | July 2024 International Release |
11. | Procedure | Angioplasty procedures In response to several enquiries from members about the apparent duplication of concepts and descriptions for procedures representing 'Percutaneous transluminal angioplasty' an analysis of the content in this area is underway. It is expected to result in inactivation of duplicates, updates to the descriptions of published concepts and remodeling to represent the imaging guidance aspect where appropriate. After the analysis of the impact has been completed, a Briefing Note will be dispatched to provide details of the changes. Examples of potential duplication:
| Q3 2024 International Release |
12. | Procedure | Review 1263452006 |Anesthesia and/or sedation procedure (procedure)| A review of the 1263452006 |Anesthesia and/or sedation procedure (procedure)| hierarchy is in progress, the focus is on:
| Q3 2024 International Release |
13. | Procedure | Review 48537004 |Bypass graft (procedure)| A review of the 48537004 |Bypass graft (procedure)| hierarchy is in progress, the focus is on:
| Q3 2024 International Release |
14. | Procedure | Review Use of 424876005 |Surgical approach (attribute)| A review to generalize 424876005 |Surgical approach (attribute)| to allow non-surgical procedures to be modeled with a subtype of <<103379005 |Procedural approach (qualifier value)| is in progress.
| Q3 2024 International Release |
15. | Procedure | Review 1287742003 |Radiotherapy (procedure)| A review of 1287742003 |Radiotherapy (procedure)| hierarchy is in progress, the focus is on:
| Q3 2024 International Release |
16. | Procedure | Review 424226004 |Using device (attribute)| vs. 363699004 |Direct device (attribute)| for Modeling of Repair Procedures 424226004 |Using device (attribute)| and 363699004 |Direct device (attribute)| are used interchangeably for modeling of repair procedures within the Repair group of relationships.
| Q3 2024 International Release |
17. | Body Structure | Update for Cardiac Wall and Cardiac Segment A proposed new model for this area of content is available here. Further information is available in this briefing note. | Q3-Q4 2024 International Release |
18. | Clinical Finding Procedure Specimen | Update 'Head and Neck' and 'Head and/or Neck' A small number of concepts have been identified with FSN of “head and neck” but modeled with 774007 |Structure of head and/or neck (body structure)|. For some concepts the intention had always been disjunctive “and/or” so to minimise disruption the FSN’s will be changed to reflect this intended meaning with therefore no change in descendants. Procedures such as 430215009 |Biopsy of head and neck structure (procedure)| will be inactivated and replaced with distinct concepts for each body site as a disjunctive in this instance would be a grouper of no clinical significance and non-conformance to editorial policy. This will impact descendants who will become children of the distinct concepts. Examples of concepts to be inactivated and replaced with two distinct concepts:
Examples of concepts with model change to two role groups (finding/disorder can occur in both structures at the same time):
Examples of concepts with FSN change to 'and/or':
| July 2024 International Release |
19. | Procedure | Review of <<75506009 |Construction of stoma (procedure)| A review of the 75506009 |Construction of stoma (procedure)| hierarchy is in progress. The focus is on updating concept modeling, but there will be a small number of inactivations (<20 concepts) and description changes, where appropriate. | Q3 2024 International Release |
20. | Procedure | Update 42687005|Lymphangiogram (procedure)| and Subtypes 42687005|Lymphangiogram (procedure)| and subtypes have been reviewed as part of the content update being undertaken for: 363680008|Radiographic imaging Procedure (procedure)| and Descendants (please see item 2 above for details). Based on user feedback and review, ‘lymphangiography’ uses fluoroscopy and contrast unless an alternative imaging method such as MRI is specified. The content in this hierarchy that currently states ‘lymphangiography’ or 'lymphangiogram' with method 278110001|Radiographic imaging - action (qualifier value)| will be inactivated and replaced with a new concept which specifies the imaging modality and the use of contrast. For example: 48858003 |Lymphangiography of lower extremity (procedure)| will be inactivated and replaced by a new concept: Fluoroscopic lymphangiography of lower limb with contrast (procedure)| A new supertype concept will be added: 1336147007 |Imaging of lymphatic system (procedure)| | July 2024 International Release |
21. | Procedure | Update to 55670007 |Endodontic procedure (procedure)| and Subtypes In consultation with the Dentistry Clinical Reference Group, updates will be made to the hierarchy 55670007 |Endodontic procedure (procedure)|. This will result in approximately 25 concepts being inactivated or remodeled. Where appropriate, replacement concepts will be added. | Q3 2024 International Release |
22. | Substance | Update << 385420005 |Contrast media (substance)| The 95 subtypes of 385420005 |Contrast media (substance) will be updated. Concepts will be remodeled based on discussion with stakeholders. New substance concepts including groupers will be required. | Q3-Q4 2024 International Release |
23. | Procedure | Proposed New Model for Solid Organ and Tissue Transplant Procedures Feedback is requested for a proposed new model for solid organ and tissue transplant procedures. Please see briefing note here. Deadline to submit feedback is 15 June 2024. | 2024 International Release |
24. | Medicinal Product | Therapeutic Role Groupers Please see the follow up briefing note for further information about the inactivation of therapeutic role groupers in the Medicinal Product hierarchy. | 2024 International Release |
25. | Body Structure | Update for Lateralizable Body Structures Lateralizable body structures will be modeled by laterality with a value of "side". The changes will be made to over 4000 body structures in the July 2024 release. This will improve the classification of existing concepts. | July 2024 International Release |
...